June 18, 2013
/PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2013 Annual Meeting of Stockholders and Open House on
Tuesday, June 25
2:10 p.m. Pacific Time
The agenda for the meeting is as follows:
Annual Meeting of Stockholders (only for stockholders of record as of
April 26, 2013
Corporate Presentation –
Stanley T. Crooke
, Isis' Chairman and Chief Executive Officer
Scientific Poster Presentation and Open House
A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site,
. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.
To RSVP to attend the meeting, please go to Isis' Home Page at
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in
the United States
for the treatment of patients with HoFH. Genzyme is also pursuing marketing approval of KYNAMRO in other markets. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at
SOURCE Isis Pharmaceuticals, Inc.